DexCom trades at $74.63 per share and has stayed right on track with the overall market, gaining 8.3% over the last six ...

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of ...

DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of ...

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that Stelo, the first over-the-counter ...

By Sneha S K June 6 (Reuters) - Medical device maker Dexcom said the use of its continuous glucose monitor, G7, led to ...

With no single headline event driving DexCom (DXCM) recently, investors are watching the stock after a gain of about 21% over the past month and roughly 7% over the past 3 months. See our latest ...

Through independent moderation by Vital Findings, council members reinforced that Dexcom remains a life-changing, essential ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it will host an Investor Day on Thursday, May 14, 2026 from 1:15 PM until approximately 3:30 PM PDT (4:15 PM – 6:30 PM EDT).

(Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated ...

Customers have known for months that the Dexcom G7 continuous glucose monitoring sensor had problems. Now, the company is ...

“Too many people with diabetes suffer through painful, antiquated fingerpricks because they don’t know a better way exists,” said Jonas. “I truly believe people with diabetes deserve the absolute best ...

Dexcom says stolen G7 sensors from two scrapped lots were sold through unauthorized channels, creating infection and reading-failure risks.